比马前列素对甲状腺相关眼病眼眶脂肪组织的作用
该研究探讨比马前列素对甲状腺相关眼病(TAO)患者眼眶脂肪来源干细胞的影响,并通过小鼠实验评估球后注射的安全性。结果显示比马前列素抑制脂肪生成并促进脂肪细胞棕色化,小鼠球后注射未出现即刻不良反应,提示前列腺素类似物可能用于TAO治疗。
要点
- 比马前列素可减少TAO及对照脂肪细胞的脂质含量并促进棕色化。
- 1型和2型TAO来源细胞迁移能力和脂质含量显著高于健康对照。
- 小鼠球后注射比马前列素未改变视网膜厚度或神经节细胞功能。
核心结论
- 比马前列素抑制眼眶脂肪来源干细胞成脂并上调脂肪细胞棕色化相关通路。
- 小鼠球后注射比马前列素可耐受且无即刻不良反应。
- 结果提示前列腺素类似物未来可能用于TAO治疗。
研究设计与样本
- 体外实验:来自1型、2型TAO及对照患者的眼眶脂肪来源干细胞,±1 μM比马前列素处理,行免疫组化、RT-PCR和Western blot检测。
- 回顾性病历审查用于临床病理关联。
- 小鼠实验:球后注射比马前列素,基线和1个月行OCT和图形ERG,随后眶内容剜除行组织病理检查。
主要发现
- 1型和2型TAO来源细胞迁移能力和脂质含量显著高于健康对照。
- 加入比马前列素后,TAO及对照脂肪细胞脂质含量显著降低,形态转变为更小的多房脂滴。
- 比马前列素处理增加线粒体负荷和UCP-1表达,与棕色脂肪组织更新增加一致。
- 小鼠球后注射比马前列素未改变大体形态、视网膜厚度或神经节细胞功能。
临床怎么用
- 比马前列素可能通过抑制成脂和促进棕色化影响TAO眼眶脂肪组织。
- 小鼠球后注射比马前列素的耐受性支持未来临床转化探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We characterize the effect of bimatoprost on orbital adipose tissue in thyroid-associated orbitopathy (TAO) with clinicopathologic correlation. METHODS: Orbital adipose-derived stem cells (OASCs) from types 1 and 2 TAO and control patients with and without exposure to 1 μm bimatoprost were examined via immunohistochemistry, RT-PCR, and Western blot for cell viability, migration capacity, lipid content, adipocyte morphology, mitochondrial content, and levels of adipogenic markers. A retrospective chart review was performed for clinicopathologic correlation. In mice, optical coherence tomography and pattern electroretinography were performed at baseline and at 1 month following a retrobulbar injection of bimatoprost, followed by orbital exenteration for histopathologic examination. RESULTS: Types 1 and 2 TAO-derived cells had a significantly higher migration capacity and lipid content than those of healthy controls. With the addition of bimatoprost, types 1 and 2 TAO and control adipocytes exhibited a significant decrease in lipid content with morphologic transformation into smaller and multilocular lipid droplets, and an increase in mitochondrial load and UCP-1 expression consistent with an increase in brown adipose tissue turnover. Retrobulbar injection of bimatoprost in mice did not alter the gross morphology, retinal thickness, or ganglion cell function in vivo. CONCLUSIONS: Bimatoprost inhibits adipogenesis in OASCs and upregulates pathways involved in the browning of adipocytes. Furthermore, retrobulbar injection of bimatoprost is tolerated without immediate adverse effects in mice. Our results suggest a potential future application of prostaglandin analogues in the treatment of TAO.
引用
- Choi CJ, Tao W, Doddapaneni R, et al. The Effect of Prostaglandin Analogue Bimatoprost on Thyroid-Associated Orbitopathy. Invest Ophthalmol Vis Sci. 2018. PMID: 30551199. doi:10.1167/iovs.18-25134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。